Filing Flows › Health Care › Lexicon Pharmaceuticals (LXRX)
Lexicon Pharmaceuticals (LXRX) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 5, 2026 · Lexicon Pharmaceuticals (LXRX) Q3 2026 earnings results →
Q3 2026 Revenue down 21% year over year to $11.2M · 124¢ of every $1 of revenue lost · operating margin -128.8%
Lexicon Pharmaceuticals made $11.2M in Q3 2026 (-21% Y/Y). Operating margin -128.8%, net loss $14.0M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 5, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $11.2M in Q3 2026, down 21% year over year and up 1526% from the previous quarter.
Operating costs exceeded revenue by $14.5M, an operating margin of -128.8%. Total costs fell 2% while revenue fell 21%. The fastest-growing cost line was Cost of revenue (+690%). The quarter ended with a net loss of $14.0M, narrower than the previous quarter's $31.8M loss.
Operating cash flow was −$8.1M. Non-cash charges added back $95K of depreciation and amortization and $3.4M of share-based compensation. Working capital and other items added $2.4M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 5, 2026 | $11.2M | -21% | -128.8% | −$14.0M | −$8.1M |
| Q2 2026 | 10-Q | Aug 6, 2026 | $692K | -98% | n/m | −$31.8M | −$9.2M |
| Q1 2026 | 10-Q | May 7, 2026 | $21.1M | 17× | -4.7% | −$1.0M | −$14.7M |
| Q4 2025 | 10-K | Mar 5, 2026 | $5.5M | -79% | -269.1% | −$15.5M | −$17.2M |
| Q3 2025 | 10-Q | Nov 6, 2025 | $14.2M | +710% | -85.9% | −$12.8M | −$23.8M |
| Q2 2025 | 10-Q | Aug 6, 2025 | $28.9M | 18× | 12.9% | $3.3M | $17.0M |
| Q1 2025 | 10-Q | May 14, 2025 | $1.3M | +12% | n/m | −$25.3M | −$43.8M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Lexicon Pharmaceuticals
We are a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. We are devoting most of our resources to the research and development of our most advanced drug candidates and the commercialization of our approved drug, INPEFA ® (sotagliflozin): • We are developing sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for hypertrophic cardiomyopathy, or HCM, and are conducting the SONATA-HCM pivotal Phase 3 clinical trial of sotagliflozin in that indication.
In its own words, from its 10-K, filed Mar 5, 2026.
Lexicon Pharmaceuticals against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -21% against the peers' median +7%. Operating margin: -128.8% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| LXRX Lexicon Pharmaceuticals | Q3 2026 | $11.2M | -21% | -128.8% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Lexicon Pharmaceuticals 10-Q on SEC EDGAR · CIK 1062822 · Pharmaceutical Preparations
Guidance and outlook
13F: who owns LXRX and who is buying
More on LXRX
- How Lexicon Pharmaceuticals makes money: revenue by segment
- Lexicon Pharmaceuticals next earnings date and what analysts expect
- Lexicon Pharmaceuticals stock forecast, price target and fair value
- Who owns Lexicon Pharmaceuticals stock: holders, funds and Congress trades
- Lexicon Pharmaceuticals guidance and outlook
- Lexicon Pharmaceuticals recalls, complaints and regulation
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results